Patents by Inventor Sunil Kher

Sunil Kher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist
    Patent number: 6251903
    Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: June 26, 2001
    Assignees: Cocensys, Inc., State of Oregon, Acting by and through the Oregon State Board of Higher Education, Acting for and on behalf of the Oregon Health Sciences University and the University of Oregon, The Regents of the University of California
    Inventors: Sui Xiong Cai, Eckard Weber, John F. W. Keana, Sunil Kher
  • Alkyl, azido, alkoxy and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist
    Patent number: 6147075
    Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: November 14, 2000
    Assignees: CoCensys, Inc., State of Oregon, Acting by and Through the Oregon State Board of Higher Education, Acting for and on Behalf of the Oregon Health Sciences University and the University of Oregon, Eugene Oregon, The Regents of the University of California
    Inventors: Sui Xiong Cai, Eckard Weber, John F. W. Keana, Sunil Kher
  • Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists
    Patent number: 5977107
    Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: November 2, 1999
    Assignees: Cocensys, Inc., State of Oregon, Acting by and Through the Oregon State Board of Higher Education, acting for and on Behalf of the Oregon Health Sciences University and the University of Oregon, Eugene Oregon, The Regents of the University of California
    Inventors: Sui Xiong Cai, Eckard Weber, John F. W. Keana, Sunil Kher
  • Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
    Patent number: 5631373
    Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.
    Type: Grant
    Filed: August 11, 1994
    Date of Patent: May 20, 1997
    Assignees: State of Oregon, acting by and through the Oregon State Board of Higher Education, acting for and on behalf of the Oregon Health Sciences University and the University of Oregon, Eugene Oregon, Acea Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Sui X. Cai, Eckard Weber, John F.W. Keana, Sunil Kher